| 11/06/2022 |
13:30 às 14:45 |
Módulo genitourinário |
13:30 às 13:35 |
5000 - TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603). |
Palestrante |
| 11/06/2022 |
13:30 às 14:45 |
Módulo genitourinário |
13:35 às 13:40 |
5002 - [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. |
Palestrante |
| 11/06/2022 |
13:30 às 14:45 |
Módulo genitourinário |
13:40 às 13:45 |
5009 - Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery. |
Palestrante |
| 11/06/2022 |
13:30 às 14:45 |
Módulo genitourinário |
14:15 às 14:45 |
Painel de discussão |
Debatedor |
